Incyte: An Undervalued Healthcare Gem

Cappuccino Finance3.34K FollowersFollow5ShareSavePlay(9min)Comment(1)SummaryIncyte is proactively addressing Jakafi's 2028 patent cliff through robust pipeline diversification and strategic acquisitions.Jakafi delivered $3.09B in 2025 sales, up 11% YoY, underpinning strong operational performance and funding for R&D.Opzelura posted 33% YoY growth with $678M in 2025 sales, highlighting successful portfolio expansion.Broader business segments achieved 121% YoY growth, demonstrating effective execution across multiple therapeutic areas. Tom Werner/DigitalVision via Getty Images Investment Thesis Incyte (INCY) is a global biopharmaceutical company that discovers, develops, and sells proprietary therapeutics. Incyte is a strong investment option for investors who are looking for an undervalued gem in the health care sector. ThanksThis article was written byCappuccino Finance3.34K FollowersFollowI believe in fundamental analysis and disciplined market research. My primary focus is to identify 1) small cap companies with strong fundamentals and growth potential, 2) large cap companies going through temporary set-backs, and 3) stable companies with solid dividend yields and growth potential.Analyst’s Disclosure: I/we have a beneficial long position in the shares of INCY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.